Table of Contents
ISRN Dermatology
Volume 2013 (2013), Article ID 616170, 10 pages
http://dx.doi.org/10.1155/2013/616170
Review Article

Melanoma M (Zero): Diagnosis and Therapy

1Melanoma and Sarcoma Unit, Veneto Institute of Oncology, IOV IRCCS, 35128 Padua, Italy
2Dermatology Unit, University of Padua, 35128 Padua, Italy
3Department of Medical Diagnostic Sciences and Special Therapies, University of Padua, 35128 Padua, Italy
4Medical Oncology Unit, Veneto Institute of Oncology, IOV IRCCS, 35128 Padua, Italy
5Institute of Anatomopathology, University of Padua, 35128 Padua, Italy
6Department of Surgical Oncological and Gastroenterological Sciences, Padua University, 35128 Padua, Italy

Received 13 February 2013; Accepted 19 March 2013

Academic Editors: M. Clelia, J. del Pozo Losada, and A. R. Ercocen

Copyright © 2013 Marco Rastrelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. M. MacKie, A. Hauschild, and A. M. Eggermont, “Epidemiology of invasive cutaneous melanoma,” Annals of Oncology, vol. 20, supplement 6, pp. vi1–vi7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Ishihara, T. Saida, F. Otsuka, and N. Yamazaki, “Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update,” International Journal of Clinical Oncology, vol. 13, no. 1, pp. 33–41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Bellew, J. Q. del Rosso, and G. K. Kim, “Skin cancer in asians part 2: melanoma,” Journal of Clinical and Aesthetic Dermatology, vol. 2, no. 10, pp. 34–36, 2009. View at Google Scholar · View at Scopus
  4. A. F. Alexis and K. Heal, “Skin cancer in skin of color,” Cutis, vol. 89, no. 5, pp. 208–211, 2012. View at Google Scholar
  5. S. Gandini, P. Autier, and M. Boniol, “Reviews on sun exposure and artificial light and melanoma,” Progress in Biophysics and Molecular Biology, vol. 107, pp. 362–366, 2011. View at Google Scholar
  6. A. M. Leung, D. M. Hari, and D. L. Morton, “Surgery for distant melanoma metastasis,” The Cancer Journal, vol. 18, pp. 176–184, 2012. View at Google Scholar
  7. L. Naldi, A. Altieri, G. L. Imberti, S. Gallus, C. Bosetti, and C. La Vecchia, “Sun exposure, phenotypic characteristics, and cutaneous malignant melanoma. An analysis according to different clinico-pathological variants and anatomic locations (Italy),” Cancer Causes and Control, vol. 16, no. 8, pp. 893–899, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Caini, S. Gandini, F. Sera et al., “Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant,” European Journal of Cancer, vol. 45, no. 17, pp. 3054–3063, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Argenziano, H. P. Soyer, S. Chimenti et al., “Dermoscopy of pigmented skin lesions: results of a consensus meeting via the internet,” Journal of the American Academy of Dermatology, vol. 48, no. 5, pp. 679–693, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Tsao, L. Chin, L. A. Garraway, and D. E. Fisher, “Melanoma: from mutations to medicine,” Genes & Development, vol. 26, pp. 1131–1155, 2012. View at Google Scholar
  11. A. H. Aguissa-Touré and G. Li, “Genetic alterations of PTEN in human melanoma,” Cellular and Molecular Life Sciences, vol. 69, pp. 1475–1491, 2012. View at Google Scholar
  12. M. James and A. A. Marghoob, “An update on risk factors, prognosis and management of melanoma patients,” Giornale Italiano di Dermatologia e Venereologia, vol. 147, pp. 1–19, 2012. View at Google Scholar
  13. S. Raimondi, F. Sera, S. Gandini et al., “MC1R variants, melanoma and red hair color phenotype: a meta-analysis,” International Journal of Cancer, vol. 122, no. 12, pp. 2753–2760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. D. S. Rigel, J. Russak, and R. Friedman, “The evolution of melanoma diagnosis: 25 years beyond the ABCDs,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 301–316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. R. M. MacKie, “Clinical recognition of early invasive malignant melanoma,” British Medical Journal, vol. 301, no. 6759, pp. 1005–1006, 1990. View at Google Scholar · View at Scopus
  16. T. D. Kokgil, T. R. Ekmekci, and S. Yasar, “Videodermoscopic pattern analysis of acral melanocytic nevi,” The Journal of Dermatology, vol. 39, pp. 290–294, 2012. View at Google Scholar
  17. H. Y. Kang, P. Bahadoran, and J. P. Ortonne, “Reflectance confocal microscopy for pigmentary disorders,” Experimental Dermatology, vol. 19, no. 3, pp. 233–239, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Garbe, K. Peris, A. Hauschild et al., “Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline,” European Journal of Cancer, vol. 46, no. 2, pp. 270–283, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. R. Marsden, J. A. Newton-Bishop, L. Burrows et al., “Revised U.K. guidelines for the management of cutaneous melanoma 2010: bad Guidelines,” British Journal of Dermatology, vol. 163, no. 2, pp. 238–256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Pflugfelder, B. Weide, T. K. Eigentler et al., “Incisional biopsy and melanoma prognosis: facts and controversies,” Clinics in Dermatology, vol. 28, no. 3, pp. 316–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. C. Ng, S. Swain, J. P. Dowling, R. Wolfe, P. Simpson, and J. W. Kelly, “The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service,” Archives of Dermatology, vol. 146, no. 3, pp. 234–239, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Jellinek, “Nail matrix biopsy of longitudinal melanonychia: diagnostic algorithm including the matrix shave biopsy,” Journal of the American Academy of Dermatology, vol. 56, no. 5, pp. 803–810, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Takata, J. Lin, S. Takayanagi et al., “Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion,” British Journal of Dermatology, vol. 156, no. 6, pp. 1287–1294, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Forschner, T. K. Eigentler, A. Pflugfelder et al., “Melanoma staging: facts and controversies,” Clinics in Dermatology, vol. 28, no. 3, pp. 275–280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Ulrich, A. J. van Akkooi, A. M. Eggermont, and C. Voit, “New developments in melanoma: utility of ultrasound imaging (initial staging, follow up and pre-SLNB),” Journal of Ultrasound in Medicine, vol. 30, pp. 1041–1049, 2011. View at Google Scholar
  26. C. A. Voit, A. C. van Akkooi, A. M. Eggermont et al., “Fine needle aspiration cytology of palpable and nonpalpable lymph nodes to detect metastatic melanoma,” Journal of the National Cancer Institute, vol. 103, no. 23, pp. 1771–1777, 2011. View at Google Scholar
  27. T. A. Aloia, J. E. Gershenwald, R. H. Andtbacka et al., “Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma,” Journal of Clinical Oncology, vol. 24, no. 18, pp. 2858–2865, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. D. L. Morton, A. J. Cochran, J. F. Thompson et al., “Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial,” Annals of Surgery, vol. 242, no. 3, pp. 302–313, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. M. A. Warycha, J. Zakrzewski, Q. Ni et al., “Meta-analysis of sentinel lymph node positivity in thin melanoma (≥1 mm),” Cancer, vol. 115, no. 4, pp. 869–879, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. C. K. Bichakjian, A. C. Halpern, T. M. Johnson et al., “Guidelines of care for the management of primary cutaneous melanoma,” Journal of the American Academy of Dermatology, vol. 65, pp. 1032–1045, 2011. View at Google Scholar
  31. M. J. Sladden, C. Balch, D. A. Barzilai et al., “Surgical excision margins for primary cutaneous melanoma,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD004835, 2009. View at Google Scholar · View at Scopus
  32. P. Gilgrenn, K. T. Drzewiecky, M. Niin et al., “2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma ticker than 2 mm: a randomized, multicentre trial,” Lancet, vol. 378, no. 9803, pp. 1635–1642, 2011. View at Publisher · View at Google Scholar
  33. A. Testori, J. Soteldo, D. Sances et al., “Cutaneous melanoma in the elderly,” Melanoma Research, vol. 19, no. 3, pp. 125–134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Mocellin, S. Pasquali, C. R. Rossi, and D. Nitti, “Validation of the prognostic value of lymph node ratio in patients with cutaneous melanoma: a population-based study of 8,177 cases,” Surgery, vol. 150, no. 1, pp. 83–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. A. J. Spillane, B. L. H. Cheung, J. R. Stretch et al., “Proposed quality standards for regional lymph node dissections in patients with melanoma,” Annals of Surgery, vol. 249, no. 3, pp. 473–480, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Martinez, W. H. Tseng, and S. E. Young, “Outcomes for lymph node-positive cutaneous melanoma over two decades,” World Journal of Surgery, vol. 35, pp. 1567–1572, 2011. View at Google Scholar
  37. C. R. Rossi, S. Pasquali, S. Mocellin et al., “Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases,” Annals of Surgical Oncology, vol. 17, no. 11, pp. 3000–3007, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. J. P. Deroose, A. M. Eggermont, A. N. van Geel, and C. Verhoef, “Isolated limb perfusion for melanoma in transit metastases: developments in recents years and the role of tumor necrosis factor alpha,” Current Opinion in Oncology, vol. 23, pp. 183–188, 2011. View at Google Scholar
  39. H. M. Kroon and J. F. Thompson, “Isolated limb infusion: a review,” Journal of Surgical Oncology, vol. 100, no. 2, pp. 169–177, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. L. G. Campana, S. Valpione, S. Mocellin et al., “Electrochemotherapy for disseminated superficial metastases from malignant melanoma,” British Journal of Surgery, vol. 99, pp. 821–830, 2012. View at Google Scholar
  41. A. Hong and G. Fogarty, “Role of radiation therapy in cutaneous melanoma,” The Cancer Journal, vol. 18, pp. 203–207, 2012. View at Google Scholar
  42. S. Mocellin, S. Pasquali, C. R. Rossi, and D. Nitti, “Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis,” Journal of the National Cancer Institute, vol. 102, no. 7, pp. 493–501, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. A. M. Eggermont, S. Suciu, M. Santinami et al., “Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial,” The Lancet, vol. 372, no. 9633, pp. 117–126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. A. M. Eggermont, S. Suciu, P. Rutkowsky et al., “Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: final results of study EORTC 18961,” Journal of Clinical Oncology, vol. 28, no. 15, article 8505, 2010. View at Google Scholar
  45. W. Kruit, S. Suciu, and B. Dreno, “Active immunization towards the MAGE-A3 antigen in patients with metastatic melanoma: four-year follow-up results from a randomized phase II study (EORTC, 16032-18031),” Journal of Clinical Oncology, vol. 29, no. article 8535, 2011. View at Google Scholar
  46. R. Kudchadkar, K. H. Paraiso, and K. S. Smalley, “Targetin mutant BRAF in melanoma: current status and future development of combination therapy strategies,” The Cancer Journal, vol. 18, pp. 124–131, 2012. View at Google Scholar
  47. U. Leiter, P. G. Buettner, T. K. Eingentler et al., “Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33, 384 patients in the German central Malignant Melanoma,” Journal of the American Academy of Dermatology, vol. 66, pp. 37–45, 2012. View at Google Scholar
  48. A. Forschner, T. K. Eigentler, A. Pflugfelder et al., “Melanoma staging: facts and controversies,” Clinics in Dermatology, vol. 28, no. 3, pp. 275–280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Savage, “Malignant melanoma, (non-metastatic),” Clinical Evidence, vol. 2007, article 1705, 2007. View at Google Scholar